Study Reveals Fibryga® Reduces Blood Component Transfusion Needs Compared to Cryoprecipitate

Analysis of FIBRES Trial: Fibryga® vs Cryoprecipitate

A recent secondary analysis of the renowned FIBRES trial has surfaced groundbreaking findings regarding the use of fibryga® (fibrinogen [human]) in reducing the need for blood transfusions in surgical patients. Published in the Journal of Cardiothoracic and Vascular Anesthesia, the study assessed two specific subgroups of patients, focusing on those not in critical condition prior to surgery and those undergoing elective surgical procedures.

Background on the FIBRES Trial

The FIBRES trial was initially designed to evaluate the efficacy of fibryga® against cryoprecipitate in managing patients who developed bleeding due to acquired fibrinogen deficiency during cardiac surgical procedures. The primary outcomes previously established indicated that fibryga® was non-inferior to cryoprecipitate. This new analysis, however, provides deeper insights into specific patient populations affected by these treatments.

Key Findings from the Secondary Analysis

The analysis identified two significant subgroups:
1. Patients in Non-Critical State (634 participants): This group made up about 86% of the primary analysis population. Results showcased a 19% reduction in the need for allogeneic blood product transfusions within the first 24 hours for patients receiving fibryga® compared to those treated with cryoprecipitate (13.6 vs 16.2 units).
2. Elective Surgery Participants (466 participants): Representing 63% of the primary population, this subgroup also experienced a 19% reduction in transfused units (11.7 units for fibryga® vs 14.4 for cryoprecipitate).

Dr. Justyna Bartoszko, the lead author of the analysis, emphasized that these findings underscore the potential for fibryga® to mitigate the risks associated with blood transfusions during and after surgery.